Related Experiment Video

Updated: Sep 26, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Eplerenone, a new selective aldosterone blocker

Ellen G McMahon1

  • 1Mail Zone T1G, Pharmacia Corporation, 800 North Lindbergh Blvd., St. Louis, Missouri 63167, USA. ellen.g.mcmahon@pharmacia.com

Current Pharmaceutical Design
|April 8, 2003
PubMed

Insights

New research shows that aldosterone, even when not blocked by common drugs, drives cardiovascular damage. The selective aldosterone blocker eplerenone demonstrates protective effects, offering potential benefits for hypertension and heart failure patients.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Activation of the renin-angiotensin-aldosterone system is linked to poor outcomes in hypertension and heart failure, contributing to end-organ damage.
  • Despite treatments like ACE inhibitors and ARBs, elevated aldosterone remains a significant cardiovascular disease risk factor.
  • Emerging preclinical evidence indicates aldosterone exerts detrimental cardiovascular effects beyond its known renal actions.

Purpose of the Study:

  • To evaluate the cardiovascular and renal protective effects of the selective aldosterone blocker eplerenone.
  • To assess the potential therapeutic benefits of eplerenone in hypertension and heart failure post-myocardial infarction.

Main Methods:

  • Preclinical studies investigating the effects of aldosterone on cardiovascular systems.
  • Experimental models of cardiovascular disease to assess eplerenone's efficacy.
  • Early clinical trials in patients with hypertension and heart failure post-myocardial infarction.

Main Results:

  • Eplerenone demonstrated significant cardioprotective and renoprotective effects in experimental cardiovascular disease models.
  • Preclinical data supports aldosterone's independent deleterious cardiovascular effects.
  • Early clinical studies suggest therapeutic potential for eplerenone.

Conclusions:

  • Selective aldosterone blockade with eplerenone shows promise in mitigating cardiovascular damage.
  • Eplerenone may offer therapeutic advantages in managing hypertension and heart failure, particularly post-myocardial infarction.
  • Targeting aldosterone offers a novel strategy for cardiovascular disease treatment.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...